New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials
Credit Justin Hicks / IPB News Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed. Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed. To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing sympt...